In summary, our findings suggest that patients treated with clopidogrel based on POC CYP2C19 genotyping experience a lower risk of MACE, including myocardial infarction, stroke, stent thrombosis, and death, as well as reduced recurrent MI. The gene discussed is CYP2C19; the disease is myocardial infarction.